How many drugs treat Multiple Sclerosis?

Drug Landscape tracks 10 marketed treatments for Multiple Sclerosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/multiple-sclerosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Multiple Sclerosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiple Sclerosis (Neurology) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Neurology 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Multiple Sclerosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zeposia	OZANIMOD	Bristol-Myers Squibb	Sphingosine 1-phosphate Receptor Modulator	Sphingosine 1-phosphate receptor 1	2020-01-01
Aubagio	TERIFLUNOMIDE	Sanofi	Pyrimidine Synthesis Inhibitor [EPC]	dihydroorotate dehydrogenase	2012-01-01
Tysabri	NATALIZUMAB	Biogen Idec	Integrin Receptor Antagonist [EPC]	α4β1 and α4β7 integrins	2004-01-01
Copaxone	GLATIRAMER ACETATE	Teva			1996-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Solu-Cortef	hydrocortisone succinate	Pfizer	Corticosteroid	Glucocorticoid receptor	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Multiple Sclerosis
· 4 drugs in Multiple Sclerosis
Generic (originally Schering) · 2 drugs in Multiple Sclerosis
Bristol-Myers Squibb · 1 drug in Multiple Sclerosis
Generic (originally Merck) · 1 drug in Multiple Sclerosis
Generic (originally Merck/Upjohn) · 1 drug in Multiple Sclerosis
Generic (originally Upjohn/Pfizer) · 1 drug in Multiple Sclerosis
Hannover Medical School · 1 drug in Multiple Sclerosis
Leiden University Medical Center · 1 drug in Multiple Sclerosis
Sanofi · 1 drug in Multiple Sclerosis
Teva · 1 drug in Multiple Sclerosis
University of California, Los Angeles · 1 drug in Multiple Sclerosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Multiple Sclerosis:

Cite this brief

Drug Landscape (2026). Multiple Sclerosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/multiple-sclerosis. Accessed 2026-06-10.

Multiple Sclerosis full disease profile — treatment pathway, diagnostics, guidelines
Neurology area landing
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing